The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection – A Systematic Review

References

• Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent clostridium difficile disease: use of high‐dose vancomycin combined with saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–1017. doi:10.1086/318130
   PubMed Web of Science ®Google Scholar
• Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection. Gastroenterology. 2019;156(5):1324–1332.e3. doi:10.1053/j.gastro.2018.12.019
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–843. doi:10.1111/apt.13144
   PubMed Web of Science ®Google Scholar
• Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73. doi:10.1016/S0140-6736(10)61266-4
   PubMed Web of Science ®Google Scholar
• Garcia PG, Chebli LA, da Rocha Ribeiro TC, et al. Impact of superimposed Clostridium difficile infection in Crohn’s or ulcerative colitis flares in the outpatient setting. Int J Colorectal Dis. 2018;33(9):1285–1294. doi:10.1007/s00384-018-3105-8
   PubMed Web of Science ®Google Scholar
• Rode AA, Chehri M, Krogsgaard LR, et al. Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Aliment Pharmacol Ther. 2021;53(9):999–1009. doi:10.1111/APT.16309
   PubMed Web of Science ®Google Scholar
• Guery B, Berger P, Gauzit R, et al. A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. J Int Med Res. 2021;49(6):030006052110212. doi:10.1177/03000605211021278
   Web of Science ®Google Scholar
• Majors D, Ellis P. Risk factors for recurrent clostridium difficile infections and strategies to decrease readmissions in a community hospital. Hosp Pharm. 2015;50(11):1003–1010. doi:10.1310/hpj5011-1003
   PubMedGoogle Scholar
• Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med. 2008;359(18):1932–1940. doi:10.1056/NEJMRA0707500
   PubMed Web of Science ®Google Scholar
• Du C, Luo Y, Walsh S, Grinspan A. Oral fecal microbiota transplant capsules are safe and effective for recurrent clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55(4):300–308. doi:10.1097/MCG.0000000000001495
   PubMed Web of Science ®Google Scholar
• Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21:2. doi:10.1016/j.cmi.2014.08.017
   Web of Science ®Google Scholar
• Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70(4):298–304. doi:10.1016/J.JHIN.2008.08.012
   PubMed Web of Science ®Google Scholar
• Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:6. doi:10.1016/j.jinf.2009.03.010
   Web of Science ®Google Scholar
• Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881–891. doi:10.1093/jac/dkt477
   PubMed Web of Science ®Google Scholar
• Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother. 1998;41(SUPPL.C):5–12. doi:10.1093/jac/41.suppl_3.5
   PubMedGoogle Scholar
• Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549
   PubMed Web of Science ®Google Scholar
• van Prehn J, Reigadas E, Vogelzang EH, et al. European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27. doi:10.1016/j.cmi.2021.09.038
   Web of Science ®Google Scholar
• Sehgal K, Zandvakili I, Tariq R, Pardi DS, Khanna S. Systematic review and meta-analysis: efficacy of vancomycin taper and pulse regimens in clostridioides difficile infection. Expert Rev Anti Infect Ther. 2022;20(4):577–583. doi:10.1080/14787210.2022.1997588
   PubMed Web of Science ®Google Scholar
• Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin. Infect Control Hosp Epidemiol. 2016;37(2):215–218. doi:10.1017/ice.2015.270
   PubMed Web of Science ®Google Scholar
• Halladay CW, Trikalinos TA, Schmid IT, Schmid CH, Dahabreh IJ. Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions. J Clin Epidemiol. 2015;68(9):1076–1084. doi:10.1016/j.jclinepi.2014.12.017
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017;64(3):265–271. doi:10.1093/cid/ciw731
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368(5):407–415. doi:10.1056/NEJMoa1205037
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:7. doi:10.1016/S0002-9270(02)04195-3
   Web of Science ®Google Scholar
• Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52:7. doi:10.1128/AAC.00090-08
   Web of Science ®Google Scholar
• Sethi AK, Al-Nassir WN, Nerandzic MM, Donskey CJ. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for clostridium difficile –associated disease. Infect Control Hosp Epidemiol. 2009;30:1. doi:10.1086/592710
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med. 2011;364:5. doi:10.1056/nejmoa0910812
   PubMed Web of Science ®Google Scholar
• Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial. Ann Intern Med. 2016;165:9. doi:10.7326/M16-0271
   Web of Science ®Google Scholar
• Deeks ED. Bezlotoxumab: a Review in Preventing Clostridium difficile Infection Recurrence. Drugs. 2017;77:15. doi:10.1007/s40265-017-0809-y
   Web of Science ®Google Scholar
• Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis. 2010;10(1):363. doi:10.1186/1471-2334-10-363
   PubMedGoogle Scholar
• Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. Int J Antimicrob Agents. 2015;46(2):205–208. doi:10.1016/j.ijantimicag.2015.03.016
   PubMed Web of Science ®Google Scholar
• Dubberke E. Strategies for prevention of Clostridium difficile infection. J Hosp Med. 2012;7(SUPPL. 3). doi:10.1002/jhm.1908
   Google Scholar